An Open-Label, Single-Sequence Study to Investigate the Effects of BMS-986165 on the Single-Dose Pharmacokinetics of Methotrexate in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 31 May 2018
At a glance
- Drugs BMS 986165 (Primary) ; Folinic acid; Methotrexate
- Indications Autoimmune disorders; Inflammatory bowel diseases; Psoriatic arthritis; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 20 Apr 2018 Status changed from recruiting to completed.
- 13 Mar 2018 Planned End Date changed from 16 Apr 2018 to 26 Mar 2018.
- 13 Mar 2018 Planned primary completion date changed from 15 Apr 2018 to 25 Mar 2018.